Deals Report: Sionna looks to AbbVie for cystic fibrosis combos as Vertex-Orum strike degrader deal

Amid a slow summer week for deal flow, venture-backed Sionna took rights to some cystic fibrosis programs in an agreement with AbbVie, while two Korean companies struck overseas deals to develop drug conjugates.

As it continues to advance a clinical pipeline of CF treatments, Sionna Therapeutics Inc. has added three more molecules to its portfolio via a July 16 deal with AbbVie Inc. (NYSE:ABBV). The private biotech gained rights to transmembrane domain 1 (TMD1)-directed CFTR corrector galicaftor (ABBV-2222) and CFTR potentiator navocaftor (ABBV-3067), both of which have completed Phase II testing, as well as TMD1-directed corrector ABBV-2851, which is in Phase I...